Clinical guidelines have recommended a target of serum uric acid (SUA) level below 6.0 mg/dL for the urate-lowering therapy (ULT) of gout patients, but there are still a high proportion of patients failing to achieve the therapeutic target above. This study aimed to identify possible predictors of poor response to ULT in gout patients.
We performed a post-hoc analysis of a multicenter randomized double-blind trial which assessed the efficacy of febuxostat in patients with hyperuricemia (serum urate level ≥ 8.0 mg/dL) and gout. Demographic characters and baseline data including SUA levels were collected. Poor response to ULT was defined as average SUA after ULT was more than 6.0 mg/dL. Factors associated with poor response to ULT in gout patients were analyzed, and multivariate logistic regression analysis was also carried out to find out those independent predictors.
A total of 370 patients were enrolled in this post-hoc analysis. Compared with those with good response to ULT, patients with poor response to ULT had younger age (P < 0.001), higher proportion of obesity (P = 0.003), higher proportion of statins use (P = 0.019), higher body mass index (BMI) (P < 0.001), higher baseline SUA (P < 0.001), higher proportion of males (P = 0.001), higher alanine transaminase (P < 0.001), higher aspartate transaminase (P = 0.017), higher total cholesterol (P = 0.005), higher triglyceride (P = 0.042), and higher low density lipoprotein (P = 0.037). Multivariate logistic regression analysis showed that younger age (odds ratio (OR) = 0.965, 95% CI 0.943–0.987, P = 0.002), higher BMI (OR = 1.133, 95% CI 1.049–1.224, P = 0.001), higher baseline SUA (OR = 1.006, 95% CI 1.002–1.009, P = 0.001), and no application of febuxostat therapy (OR = 0.41, 95% CI 0.25–0.68, P < 0.001) were independent predictors of poor response to ULT in patients with gout.
In patients with gout and hyperuricemia, younger age, higher BMI, and higher baseline SUA are predictors of poor response to ULT. These findings could help physicians better identify patients who may fail in ULT and give individualized treatment precisely.
The trial was registered at chinadrugtrials.org.cn in 2012 (CTR20130172).
• A post-hoc analysis of a multicenter randomized double-blind trial which assessed the efficacy of febuxostat in patients with hyperuricemia and gout was performed.
• Multivariate logistic regression analysis showed that younger age, higher BMI, and higher baseline SUA are predictors of poor response to urate-lowering therapy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
American College of Rheumatology
Body mass index
Blood urea nitrogen
Diastolic blood pressure
European League Against Rheumatism
Fasting blood glucose
Low density lipoprotein
Systolic blood pressure
Serum uric acid
Type 2 diabetes mellitus
Dalbeth N, Merriman TR, Stamp LK (2016) Gout. Lancet 388(10055):2039–2052. https://doi.org/10.1016/S0140-6736(16)00346-9
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of R (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64(10):1431–1446. https://doi.org/10.1002/acr.21772
Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, Bongartz T (2018) The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol 45(4):574–579. https://doi.org/10.3899/jrheum.170806
Zobbe K, Prieto-Alhambra D, Cordtz R, Hojgaard P, Hindrup JS, Kristensen LE, Dreyer L (2018) Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. Rheumatology. 58:836–839. https://doi.org/10.1093/rheumatology/key390
Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007-2008. Arthritis Rheum 63(10):3136–3141. https://doi.org/10.1002/art.30520
Lim SY, Lu N, Oza A, Fisher M, Rai SK, Menendez ME, Choi HK (2016) Trends in gout and rheumatoid arthritis hospitalizations in the United States, 1993-2011. Jama 315(21):2345–2347. https://doi.org/10.1001/jama.2016.3517
Xiaofeng Z, Yaolong C (2017) 2016 China guidelines for management of gout. Chin J Intern Med 55(11):892–899. https://doi.org/10.3760/cma.j.issn.0578-1426.2016.11.019
Roddy E, Mallen CD, Doherty M (2013) Gout. BMJ 347:f5648. https://doi.org/10.1136/bmj.f5648
Wood R, Fermer S, Ramachandran S, Baumgartner S, Morlock R (2016) Patients with gout treated with conventional urate-lowering therapy: association with disease control, health-related quality of life, and work productivity. J Rheumatol 43(10):1897–1903. https://doi.org/10.3899/jrheum.151199
Shiozawa A, Buysman EK, Korrer S (2017) Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. Curr Med Res Opin 33(1):117–124. https://doi.org/10.1080/03007995.2016.1239193
Schlesinger N, Dalbeth N, Perez-Ruiz F (2009) Gout–what are the treatment options? Expert Opin Pharmacother 10(8):1319–1328. https://doi.org/10.1517/14656560902950742
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liote F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29–42. https://doi.org/10.1136/annrheumdis-2016-209707
Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC (2015) Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res 67(4):588–592. https://doi.org/10.1002/acr.22469
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540–1548. https://doi.org/10.1002/art.24209
Luo H, Fang WG, Zuo XX, Wu R, Li XX, Chen JW, Zhou JG, Yang J, Song H, Duan XJ, Lin XF, Zeng XW, Zeng H (2018) The clinical characteristics, diagnosis and treatment of patients with gout in China. Zhonghua Nei Ke Za Zhi 57(1):27–31. https://doi.org/10.3760/cma.j.issn.0578-1426.2018.01.005
Graham GG, Stocker SL, Kannangara DRW, Day RO (2018) Predicting response or non-response to urate-lowering therapy in patients with gout. Curr Rheumatol Rep 20(8):47. https://doi.org/10.1007/s11926-018-0760-2
Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Liote F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ (2015) 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74(10):1789–1798. https://doi.org/10.1136/annrheumdis-2015-208237
Endocrinology CSo (2013) Chinese expert consensus on hyperuricemia and gout treatment. Chin J Endocrinol Metab 29(11):913–920
Sheer R, Null KD, Szymanski KA, Sudharshan L, Banovic J, Pasquale MK (2017) Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon Outcomes Res 9:629–639. https://doi.org/10.2147/CEOR.S139939
Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P (2014) Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med 126(2):65–75. https://doi.org/10.3810/pgm.2014.03.2741
Fei Y, Cong Y, Wei T, Guifeng S, Linli D, Shaoxian H, Yikai Y, Ting Y (2017) Analysis of factors influencing the therapeutic effect of lowering uric acid in patients with gout. Chin J Rheumatol 21(2):110–113
Choi HK, Atkinson K, Karlson EW, Curhan G (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 165(7):742–748. https://doi.org/10.1001/archinte.165.7.742
Zhou J, Wang Y, Lian F, Chen D, Qiu Q, Xu H, Liang L, Yang X (2017) Physical exercises and weight loss in obese patients help to improve uric acid. Oncotarget 8(55):94893–94899. https://doi.org/10.18632/oncotarget.22046
Cheung KJ, Tzameli I, Pissios P, Rovira I, Gavrilova O, Ohtsubo T, Chen Z, Finkel T, Flier JS, Friedman JM (2007) Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab 5(2):115–128. https://doi.org/10.1016/j.cmet.2007.01.005
Scheepers L, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A (2018) Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum 47(5):689–702. https://doi.org/10.1016/j.semarthrit.2017.09.007
Morlock R, Chevalier P, Horne L, Nuevo J, Storgard C, Aiyer L, Hines DM, Ansolabehere X, Nyberg F (2016) Disease control, health resource use, healthcare costs, and predictors in gout patients in the United States, the United Kingdom, Germany, and France: a retrospective analysis. Rheumatol Ther 3(1):53–75. https://doi.org/10.1007/s40744-016-0033-3
Winckler K, Obe G, Madle S, Kocher-Becker U, Kocher W, Nau H (1987) Cyclophosphamide: interstrain differences in the production of mutagenic metabolites by S9-fractions from liver and kidney in different mutagenicity test systems in vitro and in the teratogenic response in vivo between CBA and C 57 BL mice. Teratog Carcinog Mutagen 7(4):399–409
Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS (2009) Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 11(2):R46. https://doi.org/10.1186/ar2659
Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M (2004) Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 31(8):1575–1581
Janssen CA, Oude Voshaar MAH, Vonkeman HE, Krol M, van de Laar M (2018) A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in the Netherlands. Clin Rheumatol 37(8):2291–2296. https://doi.org/10.1007/s10067-018-4127-x
McGowan B, Bennett K, Silke C, Whelan B (2016) Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol 35(3):715–721. https://doi.org/10.1007/s10067-014-2823-8
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450–2461. https://doi.org/10.1056/NEJMoa050373
Altan A, Shiozawa A, Bancroft T, Singh JA (2015) A real-world study of switching from allopurinol to febuxostat in a health plan database. J Clin Rheumatol 21(8):411–418. https://doi.org/10.1097/RHU.0000000000000322
Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA (2005) Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 76(16):1835–1847. https://doi.org/10.1016/j.lfs.2004.10.031
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, Investigators C (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378(13):1200–1210. https://doi.org/10.1056/NEJMoa1710895
Derosa G, Maffioli P, Reiner Z, Simental-Mendia LE, Sahebkar A (2016) Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs 76(9):947–956. https://doi.org/10.1007/s40265-016-0591-2
Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS (2004) Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 148(4):635–640. https://doi.org/10.1016/j.ahj.2004.04.005
We thank Dr. Robin Wang for advice regarding statistical analysis of data.
This clinical trial conformed to principles of the Declaration of Helsinki and the Good Clinical Practice of China and was approved by the Drug Clinical Trial Ethics Committee, Shandong Provincial Hospital. All participants provided written informed consent.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Mu, Z., Wang, W., Wang, J. et al. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial. Clin Rheumatol 38, 3511–3519 (2019). https://doi.org/10.1007/s10067-019-04737-5
- Treatment outcomes
- Urate-lowering therapy